Approval from NMQAL for analytical methods of the products claimed In-House specifications is mandatory for granting registration to the In-House drug products submitted after 18/01/2022.

Registration will not be granted for such products without the approval from NMQAL for analytical methods.

This is not applicable for innovator products and WHO pre-qualified products.

The link to the previous notice relevant to the above.

(Date: 24 February 2022)

‍